Recent News

• 01.12.2026 - Emavusertib in Combination With FOLFOX/PD-1 Inhibitor ± Trastuzumab as First-Line Treatment for Untreated Unresectable Gastric and Esophageal Cancer ASCO-GI 2026 Poster
• 01.09.2026 - Curis Announces Closing of Private Placement Totaling up to $80.8 Million in Gross Proceeds
• 01.07.2026 - Curis Announces Pricing of Private Placement Totaling up to $80.8 Million in Gross Proceeds
• 12.09.2025 - Clinical Outcomes of Emavusertib Added to Azacitidine and Venetoclax Combination Therapy ASH 2025
• 12.09.2025 - Curis Provides Updated Data from its Frontline AML Triplet Study
• 11.24.2025 - Secondary CNS Lymphoma Clinical Outcomes SNO 2025 Poster
• 11.24.2025 - TakeAim Lymphoma Molecular Profiling and CNS Penetration SNO 2025 Poster
• 11.24.2025 - TakeAim Lymphoma Clinical Outcomes SNO 2025 Poster
• 11.14.2025 - Curis to Present at Upcoming 30th Annual SNO Meeting
• 11.06.2025 - Curis Provides Third Quarter 2025 Business Update

Recent Filings

• 01.08.2026 - EX-99.1 EX-99.1
• 01.08.2026 - 8-K Current report
• 11.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.13.2025 - 8-K/A Current report
• 11.06.2025 - 8-K Current report
• 11.06.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 11.06.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.06.2025 - EX-99.1 EX-99.1
• 10.24.2025 - 8-K Current report